Long-term Vitamin D and high-dose n-3 fatty acids' supplementation improve markers of cardiometabolic risk in type 2 diabetic patients with CHD

Talari, H.R. and Najafi, V. and Raygan, F. and Mirhosseini, N. and Ostadmohammadi, V. and Amirani, E. and Taghizadeh, M. and Hajijafari, M. and Shafabakhash, R. and Asemi, Z. (2019) Long-term Vitamin D and high-dose n-3 fatty acids' supplementation improve markers of cardiometabolic risk in type 2 diabetic patients with CHD. British Journal of Nutrition, 122 (4). pp. 423-430.

Full text not available from this repository.
Official URL: https://www.scopus.com/inward/record.uri?eid=2-s2....


This study was performed to evaluate the effects of vitamin D and n-3 fatty acids' co-supplementation on markers of cardiometabolic risk in diabetic patients with CHD. This randomised, double-blinded, placebo-controlled trial was conducted among sixty-one vitamin D-deficient diabetic patients with CHD. At baseline, the range of serum 25-hydroxyvitamin D levels in study participants was 6·3-19·9 ng/ml. Subjects were randomly assigned into two groups either taking 50A 000 IU vitamin D supplements every 2 weeks plus 2� 1000 mg/d n-3 fatty acids from flaxseed oil (n 30) or placebo (n 31) for 6 months. Vitamin D and n-3 fatty acids' co-supplementation significantly reduced mean (P = 0·01) and maximum levels of left carotid intima-media thickness (CIMT) (P = 0·004), and mean (P = 0·02) and maximum levels of right CIMT (P = 0·003) compared with the placebo. In addition, co-supplementation led to a significant reduction in fasting plasma glucose (β -0·40 mmol/l; 95A CI -0·77, -0·03; P = 0·03), insulin (β -1·66 μIU/ml; 95A CI -2·43, -0·89; P < 0·001), insulin resistance (β -0·49; 95A CI -0·72, -0·25; P < 0·001) and LDL-cholesterol (β -0·21 mmol/l; 95A CI -0·41, -0·01; P = 0·04), and a significant increase in insulin sensitivity (β +0·008; 95A CI 0·004, 0·01; P = 0·001) and HDL-cholesterol (β +0·09 mmol/l; 95A CI 0·01, 0·17; P = 0·02) compared with the placebo. Additionally, high-sensitivity C-reactive protein (β -1·56 mg/l; 95A CI -2·65, -0·48; P = 0·005) was reduced in the supplemented group compared with the placebo group. Overall, vitamin D and n-3 fatty acids' co-supplementation had beneficial effects on markers of cardiometabolic risk. © The Authors 2019.

Item Type: Article
Additional Information: cited By 0
Uncontrolled Keywords: 25 hydroxyvitamin D; acetylsalicylic acid; angiotensin receptor antagonist; antidiabetic agent; beta adrenergic receptor blocking agent; C reactive protein; calcium channel blocking agent; dipeptidyl carboxypeptidase inhibitor; glucose; high density lipoprotein cholesterol; hydroxymethylglutaryl coenzyme A reductase inhibitor; insulin; low density lipoprotein cholesterol; omega 3 fatty acid; placebo; vitamin D, adult; aged; arterial wall thickness; Article; cardiometabolic risk; controlled study; coronary artery disease; diabetic patient; disease marker; Doppler ultrasonography; double blind procedure; drug megadose; drug response; female; glucose blood level; high density lipoprotein cholesterol level; human; insulin blood level; insulin resistance; insulin sensitivity; Iran; long term care; low density lipoprotein cholesterol level; major clinical study; male; non insulin dependent diabetes mellitus; patient compliance; protein blood level; randomized controlled trial; supplementation; vitamin blood level; vitamin D deficiency
Subjects: Medicine
Biochemistry, Genetics and Molecular Biology
Divisions: Faculty of Medicine > Basic Sciences > Department of Biochemistry
Depositing User: ART . editor
Date Deposited: 31 Dec 2019 15:10
Last Modified: 31 Dec 2019 15:10
URI: http://eprints.kaums.ac.ir/id/eprint/4475

Actions (login required)

View Item View Item